The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.

ABSTRACT:

Objective

To examine the ability of dual mTORc1/c2 inhibitors in conjunction with lapatinib to function in a synergistic manner to inhibit cell proliferation and anchorage-independent growth in bladder cancer cell lines.

Materials and methods

We examined patient tumor samples for overexpression of pS6, p4EBP1, pAkt, and phosphorylated epidermal growth factor receptor (pEGFR) using a tissue microarray containing 84 cases. Three bladder cancer cell lines, T24, HT1376, and UM-UC-3, were analyzed for cell proliferation after treatment with mTORc1/c2 inhibitors OSI-027 or PP242. Western blots were used to verify that the drugs were inhibiting phosphorylation of target proteins within the mTOR pathway, and they were compared with rapamycin inhibition. We also analyzed cell prolife

SUBMITTER: Becker MN 

PROVIDER: S-EPMC4559860 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature